Financial Summary for FY2027 Q1

Overview of results

As the consolidated results for the first quarter of FY2027, revenue was 43,094 million yen, operating income was 7,719 million yen, ordinary income was 6,181 million yen, and net income attributable to owners of the parent was 4,367 million yen. Domestic operations are the core, with substantial contribution from 129 prescription medicines for medical use. Quarterly costs include selling, general and administrative expenses of 12,798 million yen and research and development expenses of 2,212 million yen. The full-year guidance shows revenue of 213,600 million yen and net income of 26,200 million yen, but the status of progress against quarterly figures and the impact of PPA are not detailed within the notes.

Outlook and notes

The full-year forecast for FY2026 is revenue of 213,600 million yen and net income of 26,200 million yen. Currency information is presented separately, but this document does not provide specific currency impact figures. The quarterly data include notes on provisional amounts related to confirmed PPA for Shanghai; attention should be paid to differences in amounts for FY2025 Q3 and Q4. At present, quantitative information on specific growth drivers and risk factors is insufficient, and further progress disclosures in upcoming quarterly reports are awaited.